Urotensin II and Cardiomyopathy in End-Stage Renal Disease

Zoccali, Carmine; Mallamaci, Francesca; Benedetto, Frank; Tripepi, Giovanni; Pizzini, Patrizia; Cutrupi, Sebastiano; Malatino, Lorenzo

doi:10.1161/hypertensionaha.107.101188

Cited by 18 publications

(14 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conflicting results have been reported by researchers measuring blood values of UII in patients with kidney disease. Some studies observed a lower UII concentration among subjects with CKD and ESRD whereas other studies reported higher UII concentration in patients with kidney disease [16,17]. We found that UII is significantly lower in our current study, and this is consistent with Mosenkis, et al's results [18] but differs from that of Tostune, et al [8,9].…”

Section: Multiple Regression Analysis Of Circulating Irisin With Othesupporting

confidence: 90%

Irisin is Associated with Urotensin II and Protein Energy Wasting in Hemodialysis Patients

Pang

et al. 2016

Kidney Blood Press Res

View full text Add to dashboard Cite

Aims/Introduction: Irisin is a newly identified myokine which can promote energy expenditure. Urotensin II (UII) is identified as the most potent mammalian vasoconstrictor to date. Previous studies showed that UII can aggravate insulin resistance while irisin alleviate insulin resistance. Through this study, it is our aim to elucidate if UII can induce insulin resistance and also have an association with the irisin level in hemodialysis (HD) patients. Materials and Methods: One hundred and twenty-eight patients on maintenance hemodialysis treatment and forty healthy subjects were enrolled in this study. Blood irisin concentrations and UII concentrations were measured by ELISA and RIA respectively. The body composition was analyzed by bioelectrical impedance. Results: The serum irisin levels and UII levels were both significantly lower in HD patients in comparison to that of the healthy subjects. The serum irisin levels were lower in HD patients with protein energy wasting than those of the patients without protein energy wasting. The independent determinants of circulating Ln (irisin) (the natural logarithm of irisin) were UII lean body mass and patients with protein energy wasting. Conclusions: Our results are the first to provide the clinical evidence of the association among irisin, UII, and protein energy wasting. Our results hint that UII and protein energy wasting might inhibit the release or synthesis of irisin from skeletal muscles in HD patients.

show abstract

Section: Multiple Regression Analysis Of Circulating Irisin With Othesupporting

confidence: 90%

Irisin is Associated with Urotensin II and Protein Energy Wasting in Hemodialysis Patients

Pang

et al. 2016

Kidney Blood Press Res

View full text Add to dashboard Cite

show abstract

“…However, in these patients, plasma UII levels were inversely correlated to many neurohormonal factors (84), to biomarkers of atherosclerosis, and to endothelial activation (83). Furthermore, elevated UII levels are associated with more favorable echocardiographic profiles (154) and actually predict lower overall cardiovascular risk in ESRD (155). These paradoxical findings hint at a potential protective role of UII in some forms of renal disease.…”

Section: Pathological Significance Of Uiimentioning

confidence: 99%

“…These paradoxical findings hint at a potential protective role of UII in some forms of renal disease. This role is thought to stem from the interference of UII with sympathetic and NO systems (154).…”

Section: Pathological Significance Of Uiimentioning

confidence: 99%

Role of urotensin II in health and disease

Ross

McKendy

Giaid

2010

American Journal of Physiology-Regulatory, Integrative and Comp

126

107

View full text Add to dashboard Cite

Urotensin II (UII) is an 11 amino acid cyclic peptide originally isolated from the goby fish. The amino acid sequence of UII is exceptionally conserved across most vertebrate taxa, sharing structural similarity to somatostatin. UII binds to a class of G protein-coupled receptor known as GPR14 or the urotensin receptor (UT). UII and its receptor, UT, are widely expressed throughout the cardiovascular, pulmonary, central nervous, renal, and metabolic systems. UII is generally agreed to be the most potent endogenous vasoconstrictor discovered to date. Its physiological mechanisms are similar in some ways to other potent mediators, such as endothelin-1. For example, both compounds elicit a strong vascular smooth muscle-dependent vasoconstriction via Ca 2ϩ release. UII also exerts a wide range of actions in other systems, such as proliferation of vascular smooth muscle cells, fibroblasts, and cancer cells. It also 1) enhances foam cell formation, chemotaxis of inflammatory cells, and inotropic and hypertrophic effects on heart muscle; 2) inhibits insulin release, modulates glomerular filtration, and release of catecholamines; and 3) may help regulate food intake and the sleep cycle. Elevated plasma levels of UII and increased levels of UII and UT expression have been demonstrated in numerous diseased conditions, including hypertension, atherosclerosis, heart failure, pulmonary hypertension, diabetes, renal failure, and the metabolic syndrome. Indeed, some of these reports suggest that UII is a marker of disease activity. As such, the UT receptor is emerging as a promising target for therapeutic intervention. Here, a concise review is given on the vast physiologic and pathologic roles of UII.UT receptor; somatostatin; human; experimental animals; autocrine/paracrine UROTENSIN II (UII) was initially isolated from the urophysis of the goby fish (Gillichthys mirabilis) (97). The peptide was subsequently isolated from the white sucker (Catostomus commersoni) and the carp (Cyprinus carpio). Although there were variations in the amino acid sequence near the amino terminus, in both species the UII molecule retained the COOH-terminal cyclic sequence: -Cys

show abstract

“…UII stimulates endothelial cell and smooth muscle cell proliferation. Although UII and GPR14 levels were found to be increased in the blood of diabetic patients with nephropathy [13] , their roles in the renal fibrogenesis under any conditions remain lack of direct evidence. We provide here the first evidence for the increased expression of UII mRNA and protein in the rat of the UUO rats.…”

Section: E Effects Of Uii On Ecmmentioning

confidence: 98%

The effects of urotensin II and its receptor in rat renal interstitial fibrosis

Wang

Cai

2011

Proceedings 2011 International Conference on Human Health and Biomedical Engineering

View full text Add to dashboard Cite

To observe the effects of urotensinII on renal fibrosis and its mechanism. The renal interstitial fibrosis model were induced by unilateral ureteral obstruction (UUO) in rats, and the rat renal interstitium fibroblasts (NRK-49F) were used for in vitro mechanism study. Results showed that expression of UII and UT was significantly upregulated at both mRNA and protein levels in the UUO group compared with controls; The pathological features with Masson's trichrome-staining included collagen girdleshaped in the interstitial of kidney which be ligated; UII exerted the stimulative effect on NRK-49F cell proliferation and DNA synthesis when UIIat concentrations of 10-9 and 10-8mol/L, compared with the Sham group (P<0.01); UII promoted the transdifferentiation of NRK-49F cells by stimulate the expression of the -SMA and increased the accumulation of ECM. We concluded that The expression of UII and GPR14 in renal tubular interstitium of UUO rats was increased significantly, and UII may play a crucial role in the progression of kidney fibrosis.

show abstract

Urotensin II and Cardiomyopathy in End-Stage Renal Disease

Cited by 18 publications

References 51 publications

Irisin is Associated with Urotensin II and Protein Energy Wasting in Hemodialysis Patients

Irisin is Associated with Urotensin II and Protein Energy Wasting in Hemodialysis Patients

Role of urotensin II in health and disease

The effects of urotensin II and its receptor in rat renal interstitial fibrosis

Contact Info

Product

Resources

About